论文部分内容阅读
目的:探讨雌激素调节基因组蛋白脱乙酰基酶6(HDAC6)的表达与乳腺癌临床病理学参数、预后及辅助三苯氧胺(TAM)内分泌治疗疗效的关系,明确HDAC6对辅助内分泌治疗的指导地位。方法:采用免疫组化方法检测93例雌激素受体(ER)阳性原发乳腺癌HDAC6的表达,统计学分析其与临床病理学参数及预后的关系。结果:①原发ER(+)乳腺癌HDAC6的阳性表达为27.96%②HDAC6表达与临床分期、肿瘤大小密切相关,在肿瘤比较大、临床分期晚的患者中高表达(P<0.05),与患者年龄、月经状态、腋淋巴结转移数目、PR状态、CerbB-2状态无相关性。③HDAC6与ER(+)乳腺癌的生存期呈负相关,生存期大于10年组中HDAC6阳性率明显低于生存期小于10年组(P<0.05);Kaplan-Meiler分析表明HDAC6是预测DFS的预后因素。结论:在ER(+)乳腺癌HDAC6与生存期呈负相关,是预后差的指标,而且是预测ER阳性乳腺癌患者辅助内分泌治疗疗效的敏感指标。
OBJECTIVE: To investigate the relationship between the expression of estrogen-regulated genomic protein deacetylase 6 (HDAC6) and clinicopathological parameters, prognosis and the effect of adjuvant tamoxifen (TAM) on endocrine therapy in breast cancer, and to clarify the guiding role of HDAC6 in adjuvant endocrine therapy. Methods: The expression of HDAC6 in 93 cases of estrogen receptor positive (ER) positive primary breast cancer was detected by immunohistochemistry. The relationship between HDAC6 and clinicopathological parameters and prognosis was statistically analyzed. Results: ① The positive expression of HDAC6 in primary ER (+) breast cancer was 27.96%. ② The expression of HDAC6 was closely related to clinical stage and tumor size, and was highly expressed in patients with relatively large tumor and late clinical stage (P <0.05) , Menstrual status, the number of axillary lymph node metastasis, PR status, CerbB-2 status no correlation. ③ The survival rate of HDAC6 and ER (+) breast cancer was negatively correlated, and the positive rate of HDAC6 in the group of survival more than 10 years was significantly lower than that of survival less than 10 years (P <0.05); Kaplan-Meiler analysis showed that HDAC6 was the predictor of DFS Prognostic factors. CONCLUSION: HDAC6 is negatively correlated with survival in ER (+) breast cancer and is a poor prognostic marker. It is also a sensitive predictor of the efficacy of adjuvant endocrine therapy in patients with ER-positive breast cancer.